首页 > 抗体蛋白 > 抗体
Ultra-LEAF™ Purified anti-human CD28 Antibod
产品名称:
Ultra-LEAF™ Purified anti-human CD28 Antibod
产品类别:
抗体
产品编号:
302944
产品应用:
302944
[价格]
规格 价格 库存
25mg ¥ 16896 1

产品详情

Product Details

Verified Reactivity
Human, Cynomolgus, Rhesus
Reported Reactivity
Baboon, Capuchin Monkey, Chimpanzee, Pigtailed Macaque, Sooty Mangabey, Squirrel Monkey
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
0.2 ?m filtered in phosphate-buffered solution, pH 7.2, containing no preservative. Endotoxin level is <0.01 EU/?g of the protein (<0.001 ng/?g of the protein) as determined by the LAL test.
Preparation
The Ultra-LEAF? (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.
Concentration
The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. Older lots may have also been bottled at 1 mg/mL. To obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF? solution contains no preservative; handle under aseptic conditions.
Application

FC - Quality tested
IHC-F, Costim, FA - Reported in the literature, not verified in house

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 1.0 ?g per million cells in 100 ?l volume or 100 ?l of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

The Ultra-LEAF? Purified antibody (Endotoxin < 0.01 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for highly sensitive assays.

Application References

(PubMed link indicates BioLegend citation)
  1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
  2. Nunes J, et al. 1993. Biochem. J. 293:835.
  3. Calea-Lauri J, et al. 1999. J. Immunol. 163:62.
  4. Tazi A, et al. 1999. J. Immunol. 163:3511. (IHC)
  5. Marti F, et al. 2001. J. Immunol. 166:197. (Costim)
  6. Jeong SH, et al. 2004. J. Virol. 78:6995. (Costim)
  7. Rivollier A, et al. 2004. Blood 104:4029. (Costim)
  8. Scharschmidt E, et al. 2004. Mol. Cell Biol. 24:3860. (Costim)
  9. Sheng W, et al. 2007.Elsevier 580:6819. PubMed
  10. Mitsuhashi M. 2007. Clin Chem.53:148. PubMed
  11. Ye Z, et al. 2008. Infect. Immun. 76:2541. PubMed
  12. Magatti M, et al. 2008. Stem Cells 26:182. (FA) PubMed
  13. Yoshino N, et al. 2008. Exp. Anim. (Tokyo) 49:97. (FC)
  14. Berg M, et al. 2008. J Leukoc Biol. 83:853. (IP) PubMed
  15. Rout N, et al. 2010. PLoS One 5:e9787. (FC)
  16. Leonard JA, et al. 2011. J. Virol. 85:6867. PubMed
  17. Nomura T, et al. 2012. J. Virol. 86:6481. PubMed
Product Citations
  1. Zheng G, et al. 2021. Signal Transduct Target Ther. 6:236. PubMed
  2. Tocheva AS, et al. 2020. Curr Protoc Immunol. 130:e103. PubMed
  3. Sungur CM, et al. 2022. J Clin Invest. Online ahead of print. PubMed
  4. Pozzetto B, et al. 2021. Nature. 600:701. PubMed
  5. Liu Y, et al. 2021. Immunol Cell Biol. 99:697. PubMed
  6. Yuan X, et al. 2022. J Extracell Vesicles. 11:e12235. PubMed
  7. Wu SY, et al. 2021. J Immunother Cancer. 9: . PubMed
  8. Amiad-Pavlov D, et al. 2021. Sci Adv. 7: . PubMed
  9. Romero-Olmedo AJ, et al. 2022. Nat Microbiol. 7:195. PubMed
  10. Nicolas P, et al. 2022. J Exp Med. 219:. PubMed
  11. Yi K, et al. 2022. Front Immunol. 12:802795. PubMed
  12. Bellini N, et al. 2022. iScience. 25:105234. PubMed
  13. Wang C, et al. 2021. Cell Stem Cell. . PubMed
  14. Zhao J, et al. 2021. Front Immunol. 12:658420. PubMed
  15. Kwon M, et al. 2020. Clin Cancer Res. 1644:26. PubMed
  16. Wei JL, et al. 2021. J Immunother Cancer. 9: . PubMed
  17. Vanshylla K, et al. 2022. Cell Host Microbe. 30:69. PubMed
  18. Naaber P, et al. 2022. Cell Rep Med. 3:100716. PubMed
  19. Wang J, et al. 2022. Nat Commun. 13:6866. PubMed
  20. Schofield DJ, et al. 2021. MAbs. 13:1857100. PubMed
  21. Blewett M, et al. 2016. Sci Transl Med. 8: 356ra119. PubMed
  22. Grandclaudon M, et al. 2019. Cell. 179:432. PubMed
  23. Jung Y, et al. 2021. Nat Commun. 12:3872. PubMed
  24. Lerrer S, et al. 2021. iScience. 24:103020. PubMed
  25. Camviel N, et al. 2022. J Immunother Cancer. 10:. PubMed
  26. Smith CM, et al. 2021. Biochem J. 478:3331. PubMed
  27. Chan W, et al. 2021. Immunohorizons. 5:117. PubMed
  28. Saragovi A, et al. 2020. Elife. 9:00. PubMed
  29. Gurusamy M, et al. 2021. Nat Commun. 12:6798. PubMed
  30. Williamson LM, et al. 2021. NPJ Precis Oncol. 5:103. PubMed
  31. Fuseini H, et al. 2022. Front Immunol. 12:796898. PubMed
  32. Glassman CR, et al. 2021. Cell. 184(4):983-999.e24. PubMed
  33. Lin M, et al. 2015. Immunol Lett. 165:26. PubMed
  34. Han K, et al. 2021. Nat Metab. 3:318. PubMed
  35. Kinloch NN, et al. 2021. Nat Commun. 12:165. PubMed
  36. Sadik A, et al. 2020. Cell. 1252:182. PubMed
  37. Wen T, et al. 2022. Cancer Immunol Res. 10:162. PubMed
  38. Dahal S, et al. 2022. Retrovirology. 19:18. PubMed
  39. Collins DR, et al. 2021. Immunity. 54:2372. PubMed
  40. McBrien JB, et al. 2020. Nature. 578:154. PubMed
  41. Sun T, et al. 2019. Haematologica. 105:661. PubMed
  42. Texler B, et al. 2021. Cell Mol Gastroenterol Hepatol. 13:383. PubMed
  43. Fang F, et al. 2021. Cell Rep. 37:109981. PubMed
  44. Wang T et al. 2018. Immunity. 49(3):504-514 . PubMed
  45. Hirschberger S, et al. 2021. EMBO Mol Med. 13:e14323. PubMed
  46. Si J, et al. 2020. Cancer Cell. 38(4):551-566.e11. PubMed
  47. Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed
  48. Sabag B, et al. 2022. Cancers (Basel). 14:. PubMed
  49. Jiang J, et al. 2021. Front Immunol. 12:785549. PubMed
  50. Rousso-Noori L, et al. 2021. Nat Commun. 12:3615. PubMed
  51. Clayton KL, et al. 2021. Cell Host Microbe. 29(3):435-447.e9. PubMed
  52. Olafsdottir TA, et al. 2022. Commun Biol. 5:914. PubMed
  53. Zhu P, et al. 2022. Cell Commun Signal. 20:121. PubMed
  54. Niu M, et al. 2021. Cell Reports. 36(8):109611. PubMed
  55. Kotanides H, et al. 2020. Mol Cancer Ther. 988:19. PubMed
  56. Chen PM, et al. 2022. Sci Adv. 8:eabo4271. PubMed
  57. Davis-Marcisak EF, et al. 2021. Genome Med. 13:129. PubMed
RRID
AB_11150591 (BioLegend Cat. No. 302933) AB_11148949 (BioLegend Cat. No. 302934) AB_2616667 (BioLegend Cat. No. 302943) AB_2616668 (BioLegend Cat. No. 302944) AB_2800748 (BioLegend Cat. No. 302959) AB_2800749 (BioLegend Cat. No. 302960)

Antigen Details

Structure
Ig superfamily, type I transmembrane glycoprotein, homodimer, 44 kD
Distribution

Mature T cells, thymocytes, NK cell subsets, plasma cells, EBV-positive B cells

Function
T cell costimulation
Ligand/Receptor
CD80, CD86
Cell Type
B cells, NK cells, Plasma cells, T cells, Thymocytes, Tregs
Biology Area
Costimulatory Molecules, Immunology
Molecular Family
CD Molecules
Antigen References

1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
2. June CH, et al. 1994. Immunol. Today 15:321.
3. Linskey PS, et al. 1993. Annu. Rev. Immunol. 11:191.

Gene ID
940 View all products for this Gene ID
UniProt
View information about CD28 on UniProt.org

联系我们

TEL:021-34661275  点击拨打热线